$322.75
5.421.71%
Last update: Oct 30, 4:03 PM
Ligand Pharmaceuticals Inc
LGNDNASDAQ
Ligand Pharmaceuticals (LGND) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ligand Pharmaceuticals (LGND) last issued guidance on October 29, 2026 for fiscal year 2026. The company guided earnings per share in the range of $9.5 - $9.75, compared to a consensus EPS estimate of $8.53. Ligand Pharmaceuticals also guided revenue in the range of $225M - $250M for the period.
Compared to prior guidance, Ligand Pharmaceuticals raised its EPS outlook from a previous range of $9 - $9.5. On the revenue side, the company lowered its revenue forecast from a prior range of $270M - $310M.
Ligand Pharmaceuticals has issued 27 guidance updates between November 7, 2022 and October 29, 2026. During this period, the company raised its outlook 15 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.15 | $1.84 | $1.64 | $1.15 |
| Actual | $2.67 | $2.37 | $1.63 | $2.02 |
| Surprise | +24.2% | +28.8% | -0.61% | +75.6% |
| Revenue | ||||
| Estimate | $77.2M | $63.5M | $59.1M | $56.6M |
| Actual | $78.7M | $63.7M | $51.7M | $59.7M |
| Surprise | +1.93% | +0.23% | -12.4% | +5.38% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $2.84 | $2.30 |
| Revenue | ||
| Consensus | $96.1M | $76.1M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $2.67 | $2.15 | 24.2 % |
| Q2 | Aug 6, 2026 | $2.37 | $1.84 | 28.8 % |
| Q1 | May 7, 2026 | $1.63 | $1.64 | -0.61 % |
| Q4 | Feb 26, 2026 | $2.02 | $1.15 | 75.6 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $78.70M | $77.21M | 1.93 % |
| Q2 | Aug 6, 2026 | $63.69M | $63.54M | 0.23 % |
| Q1 | May 7, 2026 | $51.72M | $59.06M | -12.4 % |
| Q4 | Feb 26, 2026 | $59.67M | $56.62M | 5.38 % |
